Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
SAN DIEGO, May 10, 2024 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx,” or the “Company”) today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. (“SpinCo”) to holders of shares of the Company’s common stock on a pro rata basis (the “Spin-Off”), the Nasdaq Global Market (“Nasdaq”) informed the Company that Nasdaq intends to permit the commencement of the trading of the shares of SpinCo common stock on a “when-issued” basis after the stockholders of the Company approve the acquisition of the Company by Sanofi (the “Merger”) at the Company’s special meeting of stockholders, which will be held on May 24, 2024.